Endocrinology

Analysis of more than 18 million pregnancies sheds light on the impact various prepregnancy cardiovascular risk factors, including BMI, smoking status, and diabetes, can have on risk of adverse maternal and fetal outcomes.

Using data from more than 2000 patients followed for 16 years, a Garvan Institute of Medical Research-led team found cognitive decline in older women could help predict bone loss and fracture risk among these patients.

Data show while women with GDM wanted to be responsible for their own health, an annual reminder and combined appointments would help to screen for T2D.

Data from a phase 2 study of women with overweight or obesity and polycystic ovary syndrome suggests use of licogliflozin was associated with significant reductions in hyperinsulinemia and androgenemia in this patient population.

A 12-week trial found implementing a dietary approach using a low-fat, vegan diet could help reduce the incidence of moderate-to-severe hot flashes in postmenopausal women.

Data show SGLT2is reduced HHF in patients with both stablished HFrEF and CKD and are likely to also be effective in patients with HFpEF.

FDA cites pharmacokinetic comparability considerations remained outstanding, while no clinical deficiencies on efficacy and safety were reported.

Our latest emergency department case report from Brady Pregerson, MD, features a woman in her mids 30s presenting with 2 days of gradually worsening suprapubic and right lower quadrant pain. Can you determine the correct diagnosis?

Marc Bonaca, MD, discusses a new analysis of the VOYAGER PAD trial and implications for patients with diabetes and CLI.

Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.

Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.

Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.

In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.

Investigative ORMD-0701 has potential to regulate the insulin-glucagon balance in patients.

Changes in physical activity and diet may be main cause for worsening of diabetes control.

Deepak Bhatt, MD, MPH, discusses the results of REDUCE-IT BMI, which examined effects of icosapent ethyl vs placebo based on baseline BMI, that he presented at ADA 2021.

Of the two diabetes treatments included in the study, patients with Gla-300 had lower recorded total health costs and greater commitment to treatment.

Researchers found a significant interaction between SGLT2 inhibitors based on age and eGFR.

Data show 37.5% of patients in study were found to have moderate to severe DD, with an average score of ≥2.

eGFR improved by 10.8% and creatinine decreased by 6.8% in patients who received PIT procedures.

Data show consistent benefit of finerenone on kidney and CV outcomes in patients with CKD and T2D, regardless of SGLT-2i use.

The COVID-19 pandemic has increased the usage of telemedicine tools in all medical fields.

Over half of patients attained target A1C <7%. while a third of patients attained target A1C of <8%.

Overweight/obese patients with elevated fasting blood glucose generally present with higher degrees of insulin resistance, inflammation, adverse cardiovascular disease risk profile.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The ADA study represents the first randomized head-to-head trial directly compareding an FRC with a remix insulin analog in a population of adults with suboptimally controlled type 2 diabetes on basal insulin plus OADs.

New data show liraglutide reduced visceral, ectopic fat, with greater effects seen compared to weight loss.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the semaglutide 2.4 mg (Wegovy) approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version.